Horizon deploys a powerful and flexible gene editing platform to develop genetically-modified cell lines that are driving the understanding of the role of genomics in disease, and are powering the development of novel molecular, cellular and gene therapies.
Horizon Discovery CEO, Dr. Darrin Disley, provides an update on the Horizon story
In compliance with AIM rule 26, this section of Horizon’s website contains important information for investors including business description, details of Directors and advisors, news for investors, and share information. Horizon Discovery Group plc is incorporated in England and is listed on the London Stock Exchange’s AIM market under the ticker HZD.
This site was last updated on 10/04/2017